Connecticut Innovations Invests $300,000 In Branford Cancer Tech Company

August 11, 2014: Connecticut Innovations on Monday announced a $300,000 investment in IsoPlexis, a Branford-based life science research company.

The money will be used for engineering and software updates and to finalize a beta version of its product.

“This early-stage company is making considerable advances in cancer immunotherapy,” Matthew Storeygard, senior investment associate at Connecticut Innovations, said in a statement. “The IsoPlexis micro-device and software helps drug developers identify cellular activity by providing 10 times more data per cell than the industry standard single-cell analysis tool.”

Read the rest of this article at the Hartford Courant.